Press Releases

 
Press Releases
  Date Title and Summary View
Jan 27, 2015
FREMONT, Calif., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) announced today the pricing of its initial public offering of 4,500,000 shares of common stock at a price to the public of $11.00 per share. The shares are scheduled to begin trading on the NASDAQ Capital Market under the ticker symbol "ZSAN" on January 27, ...
Dec 2, 2014
FREMONT, Calif. and INDIANAPOLIS, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Zosano) and Eli Lilly and Company (NYSE:LLY) today announced that they have entered into an exclusive agreement to develop ZP-PTH, Zosano's proprietary formulation of parathyroid hormone 1-34 (PTH) using Zosano's microneedle patch system for the treatment ...
Jun 25, 2014
Fremont, California, June 25, 2014 – Zosano Pharma Corporation, a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced the election of Troy Wilson, Ph.D., J.D., to its Board of Directors. Dr. Wilson has more than 15 years of experience in the biotechnology industry and a ...
Jun 24, 2014
Fremont, California, June 24, 2014 – Zosano Pharma Corporation (Zosano) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. The n...
Jun 14, 2014
Fremont, CA – June 14, 2014 – Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candida...
Jun 2, 2014
FREMONT, Calif., June 2, 2014 – Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, today announced the appointment of Winnie W. Tso, CPA, as Chief Financial Officer. With more than 15 years of finance, accounting and strategic management experience in the bi...
May 19, 2014
Fremont, CA — May 19, 2014 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced that Dr. Peter Daddona, the company's Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product ...
Feb 5, 2014
Fremont, California, February 5, 2014 /PRNewswire/ — Zosano Pharma, Inc., (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S (NVO) to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 (Glucagon-Like Peptide-1) analogue, to be administered once weekly using Zosano...
May 14, 2013
Fremont, CA — May 14, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the compan...
Apr 15, 2013
Fremont, CA — April 15, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics ...
Page: FirstPrevious ...
8
NextLast
= add release to Briefcase